AbbVie inks deal for Medincell's long-acting injectable platform worth up to $1.9B
AbbVie is betting more than $1.9 billion on a French biotech’s long-acting injectable technology.
The deal gives Medincell $35 million upfront and up to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
